EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review

Bianca Raffaelli iD, Roberto De Icco iD, Michele Corrado, Maria Terhart, Jessica Ailani

Cephalalgia · 2023

DOI: 10.1177/03331024221137091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cephalalgia, 2023. Verfasst von Bianca Raffaelli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcitonin gene-related peptide-targeted drugs have proven safe and effective for migraine prevention in large randomized-controlled, double-blind trials with an average duration of six months. Open-label studies may provide additional information on the long-term safety and efficacy of these substances.

Methods

We searched PubMed for open-label trials with calcitonin gene-related peptide(-receptor) monoclonal antibodies and calcitonin gene-related peptide-receptor antagonists. We summarized and critically analyzed the literature in a narrative way.

Results

Overall, 13 open-label trials were included in this review (n = 4 for erenumab, n = 4 for galcanezumab, n = 3 for fremanezumab, n = 1 for eptinezumab, n = 1 for atogepant). Open-label trial duration ranged between 12 and 264 weeks. No safety concerns emerged, and the adverse events profile was similar to the double-blind study phase. Discontinuation rates were generally low with >75% of patients remaining in the trials after one year. Efficacy data showed a sustained reduction of migraine frequency throughout the trials, along with a lasting improvement in quality of life.

Conclusions

The open-label study program for calcitonin gene-related peptide-targeted migraine preventives confirms the favorable safety and efficacy profile of these drugs over time. Treatment adherence appears higher than with previous unspecific migraine preventives. Real-world data and post-marketing surveillance studies may corroborate and complement open-label results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersHumansCalcitonin Gene-Related PeptideQuality of LifeRandomized Controlled Trials as TopicReceptors, Calcitonin Gene-Related Peptide

Stichwörter der Autor:innen

CGRPOpen-label trialmigrainemonoclonal antibodies

Substanzen

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Calcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Clinician Scientist Program, Berlin Institute of Health, Berlin, Germany.
  • Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
  • MedStar Georgetown University Hospital, Washington, DC, USA.

ORCID-Profile: Bianca Raffaelli, Roberto De Icco

Zitieren

APA

Raffaelli, B., De Icco, R., Corrado, M., Terhart, M., & Ailani, J. (2023). Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia. https://doi.org/10.1177/03331024221137091

Vancouver

Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J. Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia. 2023. doi:10.1177/03331024221137091

BibTeX
@article{Raffaelli2023,
  author = {Raffaelli, Bianca and De Icco, Roberto and Corrado, Michele and Terhart, Maria and Ailani, Jessica},
  title = {Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review},
  journal = {Cephalalgia},
  year = {2023},
  doi = {10.1177/03331024221137091}
}
Kostenlos starten →